CL2020001180A1 - Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular. - Google Patents
Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular.Info
- Publication number
- CL2020001180A1 CL2020001180A1 CL2020001180A CL2020001180A CL2020001180A1 CL 2020001180 A1 CL2020001180 A1 CL 2020001180A1 CL 2020001180 A CL2020001180 A CL 2020001180A CL 2020001180 A CL2020001180 A CL 2020001180A CL 2020001180 A1 CL2020001180 A1 CL 2020001180A1
- Authority
- CL
- Chile
- Prior art keywords
- muscular dystrophy
- treatment
- edasalonexent
- dosage regimen
- edasal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
LA INVENCIÓN PROPORCIONA MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO DE UNA DISTROFIA MUSCULAR, POR EJEMPLO, DISTROFIA MUSCULAR DE DUCHENNE (DMD), EN UN SUJETO, CON UN SALICILATO ACETILADO DE ÁCIDO GRASO, POR EJEMPLO, EDASALONEXENT, EFECTIVO PARA ALCANZAR UN UMBRAL DE CONCENTRACIÓN PLASMÁTICA DEL SALICILATO ACETILADO DE ÁCIDO GRASO EN EL SUJETO, POR EJEMPLO, UN UMBRAL DE CONCENTRACIÓN PLASMÁTICA DE AL MENOS ALREDEDOR DE 20 NG/ML DURANTE AL MENOS 12 HORAS EN UN PERIODO DE 24 HORAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581981P | 2017-11-06 | 2017-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001180A1 true CL2020001180A1 (es) | 2020-09-25 |
Family
ID=66332350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001180A CL2020001180A1 (es) | 2017-11-06 | 2020-05-05 | Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210023029A1 (es) |
| EP (1) | EP3706730A4 (es) |
| JP (1) | JP2021502328A (es) |
| KR (1) | KR20200084877A (es) |
| CN (1) | CN111315372A (es) |
| AU (1) | AU2018359969A1 (es) |
| BR (1) | BR112020009020A2 (es) |
| CA (1) | CA3078727A1 (es) |
| CL (1) | CL2020001180A1 (es) |
| CO (1) | CO2020006395A2 (es) |
| IL (1) | IL274375A (es) |
| MX (1) | MX2020004659A (es) |
| PH (1) | PH12020550526A1 (es) |
| RU (1) | RU2020118258A (es) |
| SG (1) | SG11202004115WA (es) |
| WO (1) | WO2019090271A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020191087A1 (en) * | 2019-03-18 | 2020-09-24 | Ptc Therapeutics, Inc. | Therapeutic combinations for use in treating a muscular dystrophy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2656903T3 (es) * | 2008-07-08 | 2018-02-28 | Catabasis Pharmaceuticals, Inc. | Salicilatos acetilados de ácidos grasos y sus usos |
| PL2519230T3 (pl) * | 2009-12-31 | 2019-05-31 | Marius Pharmaceuticals Llc | Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole |
| NZ601698A (en) * | 2010-01-08 | 2015-04-24 | Catabasis Pharmaceuticals Inc | Fatty acid fumarate derivatives and their uses |
-
2018
- 2018-11-05 KR KR1020207015893A patent/KR20200084877A/ko unknown
- 2018-11-05 EP EP18874489.0A patent/EP3706730A4/en not_active Withdrawn
- 2018-11-05 MX MX2020004659A patent/MX2020004659A/es unknown
- 2018-11-05 SG SG11202004115WA patent/SG11202004115WA/en unknown
- 2018-11-05 CN CN201880071203.6A patent/CN111315372A/zh active Pending
- 2018-11-05 CA CA3078727A patent/CA3078727A1/en not_active Abandoned
- 2018-11-05 BR BR112020009020-4A patent/BR112020009020A2/pt not_active Application Discontinuation
- 2018-11-05 AU AU2018359969A patent/AU2018359969A1/en not_active Abandoned
- 2018-11-05 US US16/761,783 patent/US20210023029A1/en not_active Abandoned
- 2018-11-05 JP JP2020520142A patent/JP2021502328A/ja active Pending
- 2018-11-05 RU RU2020118258A patent/RU2020118258A/ru unknown
- 2018-11-05 WO PCT/US2018/059283 patent/WO2019090271A1/en active Application Filing
-
2020
- 2020-04-30 PH PH12020550526A patent/PH12020550526A1/en unknown
- 2020-04-30 IL IL274375A patent/IL274375A/en unknown
- 2020-05-05 CL CL2020001180A patent/CL2020001180A1/es unknown
- 2020-05-27 CO CONC2020/0006395A patent/CO2020006395A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111315372A (zh) | 2020-06-19 |
| PH12020550526A1 (en) | 2021-05-10 |
| AU2018359969A1 (en) | 2020-05-14 |
| SG11202004115WA (en) | 2020-06-29 |
| RU2020118258A (ru) | 2021-12-08 |
| BR112020009020A2 (pt) | 2020-10-27 |
| US20210023029A1 (en) | 2021-01-28 |
| IL274375A (en) | 2020-06-30 |
| CA3078727A1 (en) | 2019-05-09 |
| KR20200084877A (ko) | 2020-07-13 |
| WO2019090271A1 (en) | 2019-05-09 |
| CO2020006395A2 (es) | 2020-06-09 |
| JP2021502328A (ja) | 2021-01-28 |
| EP3706730A4 (en) | 2021-08-11 |
| EP3706730A1 (en) | 2020-09-16 |
| MX2020004659A (es) | 2020-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
| DOP2017000272A (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2017002031A1 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| PH12020500076A1 (en) | Long-acting formulations | |
| AR102085A1 (es) | Composición nutricional para el entorno gastrointestinal para la provisión de un perfil metabólico y microbioma mejorados | |
| EA201790442A1 (ru) | Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae | |
| CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
| CO2020004034A2 (es) | Métodos para el tratamiento de distrofia muscular | |
| MX2016011938A (es) | Composicion farmaceutica liquida. | |
| PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
| CL2019002985A1 (es) | Método para preparar una composición con un bajo contenido de oxígeno disuelto, que comprende paracetamol, y opcionalmente uno o más aine, y una composición obtenida de la misma. | |
| CL2020001180A1 (es) | Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular. | |
| AR099558A1 (es) | Régimen de dosaje del compuesto fgf-18 | |
| NZ713440A (en) | Nsaid administration and related compositions, methods and systems. | |
| CO2019007531A2 (es) | 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos | |
| EA202090287A1 (ru) | Составы пролонгированного действия | |
| PH12016502547A1 (en) | Methods for treating infections | |
| UA97716U (uk) | Лікарський засіб у формі сиропу, що містить фенспіриду гідрохлорид | |
| UA91608U (uk) | Спосіб очищення кишечнику |